| 7.87 -0.07 (-0.88%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.09 | 1-year : | 12.96 |
| Resists | First : | 9.5 | Second : | 11.09 |
| Pivot price | 7.86  |
|||
| Supports | First : | 6.92 | Second : | 5.32 |
| MAs | MA(5) : | 8.76 |
MA(20) : | 7.48 |
| MA(100) : | 6.43 |
MA(250) : | 4.92 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 85.6  |
D(3) : | 88.9 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 9.5 | Low : | 2.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CDXC ] has closed below upper band by 13.7%. Bollinger Bands are 58.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.32 - 9.37 | 9.37 - 9.41 |
| Low: | 8.62 - 8.66 | 8.66 - 8.7 |
| Close: | 8.88 - 8.95 | 8.95 - 9.02 |
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Tue, 25 Mar 2025
Why ChromaDex Corp (CDXC) Is Surging In 2025? - Yahoo Finance
Thu, 13 Mar 2025
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Thu, 13 Mar 2025
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire
Thu, 06 Mar 2025
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
Wed, 05 Mar 2025
ChromaDex Stock Jumps: Unpacking The Surge - StocksToTrade
Tue, 04 Mar 2025
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 34.7 (%) |
| Held by Institutions | 30 (%) |
| Shares Short | 2,110 (K) |
| Shares Short P.Month | 2,110 (K) |
| EPS | 0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 8.5 % |
| Operating Margin | 24.4 % |
| Return on Assets (ttm) | 7.8 % |
| Return on Equity (ttm) | 22.9 % |
| Qtrly Rev. Growth | 37.4 % |
| Gross Profit (p.s.) | 0.79 |
| Sales Per Share | 1.28 |
| EBITDA (p.s.) | 0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 12 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | 81.36 |
| PEG Ratio | 0 |
| Price to Book value | 14.91 |
| Price to Sales | 6.98 |
| Price to Cash Flow | 57.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|